semaglutide step 1 STEP-HFpEF Trial Once-weekly semaglutide 7·2 mg in

HTN, HTN130, HTN140, and RH

described multiple HFpEF phenotypes with variable regional propensities, including, Diabetic obese (North America), Hypertensive women (Latin America), and, Young ischemic (Eastern Europe) [6]

The goal is not to compete with pharma

PlexusDx takes a precision-wellness approach: understanding your genetic predispositions in GLP-1 receptor pathways may help contextualize how your body responds to medication administration across different sites

High out-of-pocket costs for medications like Zepbound or Wegovy can also pose significant financial burdens, making it essential to advocate for your coverage